CYP2D6*10和CYP2C19*2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究  

Association between CYP2D6*10 / CYP2C19*2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment

作　　者：王莹莹[1] 程光华[1] 濮之晨 葛俊亮[1] 谢彦[1] 陈晓磊[1] 

机构地区：[1]皖南医学院弋矶山医院核医学科 [2]皖南医学院弋矶山医院临床药学部

出　　处：《中国临床药理学与治疗学》2015年第5期552-556,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:研究CYP2D6*10和CYP2C19*2基因型多态性与接受他莫昔芬(tamoxifen,TAM)治疗乳腺癌患者生存率的相关性研究。方法:选择2009至2004年本院甲乳外科和肿瘤内科收治的171名术后服用TAM治疗的雌激素阳性乳腺癌患者,调查TAM使用情况和生存状态等相关资料;收集相关的石蜡组织切片用于DNA提取;用PCR技术检测CYP2D6*10和CYP2C19*2基因型多态性;查明CYP2D6*10和CYP2C19*2基因型多态性与患者生存率的相关性。结果:本次研究中,CYP2D6Wt/Wt、CYP2D6Wt/*10和CYP2D6*10/*10基因型的总生存率(overall survival,OS)类似,差异无统计学意义(P>0.05)。CYP2C19*2/*2基因型的5年OS明显优于CYP2C19 Wt/Wt,差异具有统计学意义(P<0.05);CYP2C19*2/*2基因型的10年OS明显优于CYP2C19 Wt/Wt和CYP2C19 Wt/*2,差异具有统计学意义(P<0.05);但是CYP2C19Wt/Wt与CYP2C19 Wt/*2的5、10年OS差异无统计学意义(P>0.05)。结论:研究结果显示,CYP2D6*10基因型多态性与服用TAM治疗乳腺癌患者的生存率之间不存在相关性;CYP2C19*2基因型多态性与接受TAM治疗乳腺癌患者的生存率之间存在相关性,CYP2C19*2/*2接受TAM治疗乳腺癌患者的生存率最高,CYP2C19 Wt/*2生存率较高,CYP2C19 Wt/Wt较低。AIM： To observe the association between CYP2D6＊10 and CYP2C19＊2 genotype polymorphism and survival of breast cancer patient receiving tamoxifen（ TAM） treatment. METHODS：171 cases of breast cancer patient receiving TAM treatment were selected from breast surgery and medical oncology since 2004-2009. The service condition of TAM treatment and the survival state were examined,the paraffin section of patients were collected and used in DNA extract,the CYP2D6＊10 and CYP2C19＊2 genotype polymorphism were detected by PCR,and the association between CYP2D6＊10and CYP2C19＊2 genotype polymorphism and survival of breast cancer patient receiving TAM treatment were ascertained. RESULTS： Overall survival（ OS） of CYP2D6Wt/Wt,CYP2D6Wt/＊10 and CYP2D6＊10 /＊10 were very similar（ P〈0. 05）. 5years-OS of CYP2C19＊2 /＊2 were significantly higher than that of CYP2C19 Wt / Wt group,and the difference was statistically significant（ P〈0. 05）;10 years-OS of CYP2C19＊2 /＊2 were significantly higher than that of CYP2C19 Wt / Wt or CYP2C19 Wt /＊2,and the difference was statistically significant（ P〈0. 05）; 5 or 10 years-OS of CYP2C19 Wt / Wt was similar to that of CYP2C19 Wt /＊2（ P〈0. 05）. CONCLUSION： The CYP2D6＊10 genotype polymorphisms isn＇t associated with survival of breast cancer patient receiving TAM treatment. The CYP2C19＊2 genotype polymorphism is associated with survival of breast cancer patient receiving TAM treatment. The survival rate of breast cancer patient with CYP2C19＊2 /＊2 receiving TAM treatment is the highest,that of CYP2C19 Wt /＊2 is medium,and that of CYP2C19 Wt / Wt is lower.

关 键 词：CYP2D6＊10 CYP2C19＊2 乳腺癌 他莫昔芬 

分 类 号：R737.9[医药卫生—肿瘤]